CTLA4 and colorectal cancer: To determine if an anti-IFNγ immunoPET tracer could identify intratumoral immune activity after ICI, we utilized BALB/c mice bearing subcutaneous CT26 colorectal cancer as a responsive model for combined ICI (anti-CTLA4 and anti-PD-1) therapy.